May 16, 2025

Ref:- GHL/2025-26/EXCH/19

The General Manager The Manager

Dept. of Corporate Services Listing Department
BSE Limited, National Stock Exchange of India Limited
P J Towers, Dalal Street, Exchange Plaza, C-1, Block G,
Mumbai - 400 001 Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 543654 Symbol: MEDANTA

Sub: Investor Presentation

Dear Sir(s),
Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015, please find enclosed herewith the revised Investor Presentation for
the fourth quarter and financial year ended March 31, 2025 Results.

Kindly refer to slide no 13, 19, 22 and 26 of the presentation for the changes and also refer to the note
“Matured and Developing hospitals numbers have been restated due to the merger of MHPL (Lucknow
Unit) with GHL (holding company). The intercompany transactions between two companies were
eliminated as per the requirement of accounting standards.”

Kindly take the above on record.

Thanking you,

Yours faithfully

For Global Health Limited

RAHUL Digitally signed by

RAHUL RANJAN

RANJAN [Link] +05'30'

Date: 2025.05.16

Rahul Ranjan
Company Secretary & Compliance Officer
M. No. A17035

Encl: a/a

Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 [Link], info@[Link], CIN: L85110DL2004PLC128319
GLOBAL HEALTH LIMITED
Dedicated to Life

Investor Presentation
Q4 and FY2025
5
15th May, 2025

1
Disclaimer

This presentation, apart from historical information, contains some "forward-looking

statements" including those describing the Company’s strategies, strategic direction,
objectives, future prospects, estimates etc. These forward-looking statements involve a
number of risks, uncertainties and other factors that could cause actual results to differ
materially from those suggested by these statements. These factors include, but are not
limited to general market conditions, macro-economic, movements in currency exchange and
interest rates, the ability to attract and retain high quality human resource, competitive
pressures, technological developments, governmental and regulatory trends, legislative
developments, and other key factors beyond the control of the Company.

These forward looking statements are based on information currently available to us, and we
assume no obligation to revise these statements as circumstances change. The Company may
alter, modify or otherwise change in any manner the content of Presentation/Press Release,
without obligation to notify any person of such revision or changes.

2
Contents
01 FY2025: Year at a Glance

02 FY2025 Performance Update

03 Q4 FY2025 Performance Update

04 Project Update and Capex Plan

05 Medanta’s Journey, Purpose and Model of Healthcare

06 Annexures

3
01 FY2025: Year at a Glance

4
 One of the largest private hospital chains in North and East India
Serving over 400 million people in the States with Medanta facilities

Gurugram; Largest single location

private hospital in with operational
Delhi; ~1,150 bed addition bed capacity of 1,440 Our Network
planned with 750 beds in
Pitampura and 400 beds in
South Delhi
Noida; 550 beds super Hospital Network Bed Capacity Infrastructure
speciality hospital
Guwahati; Planned 400
5 Multi-speciality
hospitals
3,042 Total Beds 720+ ICU Beds

bed super-specialty hospital Planned Bed Operating

to serve entire Northeast 6 Upcoming hospitals ~3,000 Addition 80+ Theatres
92 Delhi / NCR region

Lucknow; Largest Gurugram

Uttar Pradesh

private hospital in 64
Guwahati
Uttar Pradesh Lucknow 60 Assam
Bihar
with planned bed
capacity of 950 Patna Continuity of care
Jharkhand

Madhya Pradesh Medanta Clinics Medanta Labs Pharmacy

Ranchi
Indore 36

Patna; Largest private

8 Clinics 11 Labs total 8 Pharmacy
Indore; 175
bedded hospital hospital in Patna with 5 cities 300+ Collection centre 10+ Planned
planned bed capacity of 650
Maharashtra

Mumbai
Ranchi; 2nd largest private
Mumbai; ~500 beds hospital in Ranchi bed
super speciality capacity of 200
hospital under New 110 bedded hospital to Our People
construction at be operationalized under an
O&M arrangement
Oshiwara Nurses and Full-time and
Doctors
paramedics retainer employees

1,800+ 7,000+ 11,800+

Existing Hospital Upcoming Hospital

Medanta Labs Medanta Clinics

Existing Hospital : 1. Gurugram, 2. Indore, 3. Ranchi, 4. Lucknow 5. Patna

Upcoming Hospitals: 1. Ranchi, 2. Noida, 3. Mumbai, 4. Pitampura, New Delhi 5. South Delhi, 6. Guwahati 5
 Executing strategic priorities with consistency
Strengthening the core and building strong pipeline for growth

Capacity Expansion Attract Best Talent

 Consolidated: Total 219 beds added during the year, 7.8% bed growth  119+ Doctors on-boarded in FY25 across Medanta
network hospitals
 Gurugram: Inaugurated dedicated floor for mother and child with 49 beds
(including 25+ dedicated neonatal beds) in Q1 FY25  45+ senior clinicians; on-boarded during the year

 Lucknow: Total 98 beds added in March 2024 and 58 beds added in FY2025  Strengthening clinical capability through talent
additions
 Patna: Total 112 beds including 55 census beds and 57 day care beds comprising
of 39 Dialysis and 17 Chemo beds added in FY2025

 Ranchi: Lease agreement signed to operate and manage a newly built 110
bedded hospital in Ranchi, expected to operationalize in Q1 FY26

 Noida with total capacity of 550 beds: Construction in full swing, 300 beds
expected to operationalise by Q2 FY26
Continuity of Care
 Mumbai: Land acquired in Mumbai in October 2024. Barricading of the land is
complete. Architectural drawings are currently under preparation  2 new labs, 1 National Reference Laboratory and 100+
collection centres added in FY2025, taking total labs to
 Pitampura, New Delhi: Signed O&M Agreement to operate and manage a ~750 11 and collections centre to 225+
bedded hospital. To be jointly built by Medanta and Society. Architectural
drawings are currently under preparation  7 new retail pharmacy operationalized outside of
hospitals during the year
 Guwahati, Assam: Board has approved project to build a 400 bedded hospital
 2 new Medanta clinics launched in Gurgaon and
in Guwahati. Land purchase is in progress (announced in April, 2025) Ranchi

6
Advancing care: New equipment additions in FY2025
Providing the latest tools to enable our doctors to deliver the greatest care
Medanta Gurugram Medanta Lucknow

Magnetom Vida MRI System Da Vinci Xi Single robotic system Surgical Robot (Da Vinci)

s
with Paradigm Generator single console

New Cath Lab- Artis ICG Auto Fluorescence

SSI MANTRA 3.0
Zee Floor 20x 20 Imaging System

7
FY2025 clinical achievements
Continuing the legacy of clinical excellence

Medanta Lucknow successfully performed the Group’s first CAR-T cell therapy, marking a significant milestone in advanced cancer
care. Following this, Medanta Gurugram also conducted CAR-T cell therapy—an innovative treatment that leverages the patient’s own
immune system to combat cancer

Medanta Lucknow becoming known as a centre of excellence for robotic surgeries in Uttar Pradesh. 100+ robotic surgeries in first 6
months

Medanta Lucknow crossed the milestone of 250+ kidney transplants since inception. Establishing itself as a leading centre for renal
transplantation in the region

Medanta Gurugram successfully addresses a complex case of peripheral arterial disease with Stealth Orbital 360 Atherectomy –
setting a new standard of care, with a focus on re-intervention if needed in a 'leave no metal behind' approach

s
Medanta Patna saves infant through early detection of Trichohepatoenteric Syndrome - one of world's rarest disorders

Medanta Gurugram patents Brachytherapy device MAOLO for advanced Cervical Cancer treatment

Medanta Gurugram doctors uses minimally invasive unique approach to treat rare heart condition Idiopathi Chylopericardium

Medanta Gurugram successfully performed a complex 14-hour surgery on a 2-year-old boy to remove a rare facial tumour
(Myofibroblastoma)

8
Merger of wholly owned subsidiary MHPL with GHL completed in March
2025, with appointed date as 1st April, 2024

Current Structure  Proposed merger of a wholly owned subsidiary MHPL with and into GHL by undertaking the scheme
of amalgamation w.e.f. 1st April, 2024
Promoters Public
 MHPL runs a hospital in Lucknow, Uttar Pradesh which is referred to as “Medanta Lucknow Hospital”
33.07% 66.93%

 The rationale for the merger includes:

GHL o Streamline legal, regulatory, and record-keeping processes, reducing complexity and compliance
costs
100% Amalgamation of MHPL
with and into GHL
o Cost savings through reduced overhead, administrative, and managerial expenses
MHPL
o Operational synergies that drive economies of scale and enhance organizational capabilities to
better compete in a competitive industry
Immovable Property
in Lucknow
o Export benefits of GHL under the EPCG scheme will get extended to Lucknow unit post merger
o Optimized fund deployment for both organic and inorganic growth, maximizing shareholder value
Resultant Structure  The Hon’ble NCLT has approved the merger and MHPL is dissolved and merged with GHL with
appointed date as 1st April, 2024

 Non recurring one time expense provision was made amounting to INR 499 million pertaining to
Promoters Public
stamp duty payable due to merger
33.07% 66.93%
 MHPL was a wholly owned subsidiary of GHL, therefore no consideration was issued

GHL
 Merger Status and Timeline

March 2024 August 2024 January 2025 February 2025 March 2025
Board Approved Shareholders / NCLT Final Hearing, NCLT Merger MHPL Dissolved and
MHPL along Existing
with Merger Creditors Approval Order Reserved Approved merged with GHL
business
immovable
property P P P P P
9
Consistent in pursuit of clinical excellence
Recognized as Best Private Hospital in India six years in a row by Newsweek

For the Sixth year in a row, Medanta Gurugram has been recognised as
India’s best private hospital in the prestigious ‘World's Best Hospitals 2025’
ranking by Newsweek

Only Indian private hospital to feature in the elite list of top 150 hospitals,
globally

Selected from over 2,400 centres across 30 countries basis the feedback
of over 85,000 medical experts, patient surveys and public data on key
metric such as hygiene, patient-to-doctor ratio, Patient Reported Outcome
Measures (PROM)

Solidifies our position as a global healthcare leader, reflecting our

commitment to exceptional clinical quality, pioneering research, and
compassionate patient care

Together, we are proof of “Har Ek Jaan Anmol (Every Life is Invaluable)

10
02 FY2025 Performance Update

11
 FY2025 performance summary
Revenue growth of 13% y-o-y, primarily led by increase in patient volumes. Announced first ever dividend of
25% (INR 0.50 per share)

Adjusted PAT*
INR 37,714 million INR 9,562 million INR 4,813 million INR 5,186 million
Total Income

Margin: 25.4% Margin: 12.8% Margin: 13.8%

EBITDA

PAT
FY24 FY24 FY24 FY24
33,498 million
12.6% 8,737 million
Margin: 26.1% 9.4% 4,781 million
Margin: 14.3% 0.7% 4,781 million
Margin: 14.3% 8.5%

Patient Footfalls
174,219 29,37,400
Occupied Bed

552,492 62,722 3.17

ARPOB* (INR)

ALOS (days)
In-patients Out-patients
Days

FY24 FY24 FY24

503,239 9.8% 61,890 1.3% 3.23 -1.8% 11.7%% 9.5%
FY24 FY24
155,915 26,83,293

*In Q4 FY25 and FY25, PBT and PAT is impacted due to non-recurring exceptional expense item of INR 499 million arising due to merger of MHPL with GHL

1. ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days
2. Outpatients volume reflects OPD encounters 12
 FY2025 performance summary
Revenue growth of 13% y-o-y, primarily led by increase in patient volumes
• Consolidated Total Income of INR 37,714 million, grew by 12.6% y-o-y. The growth was primarily driven by increase in patient volumes

• EBITDA was INR 9,562 million, growth of 9.4% y-o-y. EBITDA margins stood at 25.4% compared to 26.1% in FY24

• Profit After Tax was INR 4,813 million, with PAT margins of 12.8%

• Profit After Tax was impacted due to non-recurring exceptional expense item of INR 499 million arising due to merger of MHPL (Lucknow entity)
with GHL. Adjusted PAT was INR 5,186 million with margins of 13.8% and growth of 8.5% y-o-y

• The board of directors have recommended a final dividend of 25% on the face value of INR 2 per share i.e. INR 0.50 per share

• During the year, 219 new beds were added, growth of 7.8% y-o-y, comprising of 49 beds at Gurugram, 58 at Lucknow and 112 beds at Patna hospital

• Occupied bed days increased by 10.0%, representing an occupancy of 62.1% on increased bed capacity

• ARPOB grew marginally by 1.3% y-o-y to INR 62,722 in FY2025

• In-patients count increased by 11.7% and Out-patients count increased by 9.5% y-o-y

• Matured hospitals revenue was INR 26,119 million, growth of 10.6% on y-o-y basis. EBITDA was INR 6,481 million, growth of 12.1% y-o-y

• Developing hospitals revenue was INR 10,940 million, growth of 10.0% on y-o-y basis. EBITDA was INR 3,290 million, growth of 1.8% y-o-y

• During the period, International Patients Revenue increased by 7.8% y-o-y to INR 2,086 million, driven by increased international patient volume

• OPD Pharmacy (Hospital & Retail) continues to register strong growth. Revenue increased by 26% y-o-y to INR 1,400 million in FY25

Notes:
 Matured and Developing hospitals number have been restated due to the merger of MHPL (Lucknow Unit) with GHL (holding company). The intercompany
transactions between two companies were eliminated as per the requirement of accounting standards
 Previous period figures have been regrouped/reclassified to conform to the current period's classification

*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days 13
FY2025 performance summary
Net cash Positon of INR 8,123 million. Well capitalized balance sheet with strong EBITDA to
cash flow conversion

Key Highlights
INR million FY2020 FY2021 FY2022 FY2023 FY2024 FY2025

Gross Debt 6,219 6,446 8,379 8,422 4,193 3,279 • Gross Debt reduced by INR 914 million

Cash and Cash Equivalents 2,740 3,081 5,222 13,114 11,913 11,402
• Net Cash surplus of INR 8,123 million at the
end of 31st March, 2025
Net Debt / (Net Cash) 3,480 3,365 3,156 (4,692) (7,720) (8,123)
• Strong operating cash flow with robust
EBITDA to cash flow conversion
Shareholder Equity 13,495 13,823 16,160 24,282 29,056 33,864
• Capex of INR 6,449 million incurred during
Net Debt to Equity (x) 0.3x 0.2x 0.2x - - the year out of which INR 1,367 million
incurred towards Mumbai hospital
Net Cash flow from Operations 1,751 2,418 3,113 6,445 6,121 6,238
• Well capitalized balance sheet to drive
EBITDA 2,305 2,229 4,898 6,771 8,737 9,562 future expansion plans and growth

Cash Flow Conversion (%) 76% 108% 64% 95% 70% 65% • The board of directors have recommended
a final dividend of INR 0.50 per share, 25%
Net Debt to EBITDA (x) 1.5x 1.5x 0.6x - - - on the face value of INR 2 per share

14
 Key operating metrics: Revenue and profitability
Consistently delivering strong CAGR growth across key financial metrics
Total Income (INR million) EBITDA (INR million and margin %)
FY2021-25 CAGR2: 26% FY2021-25 CAGR2: 44%
+12.6%
FY2020-25 CAGR: 20% FY2020-25 CAGR: 33% +9.4%
37,714
33,498 9,562
8,737
27,592
6,771
22,058
4,897
14,782
2,229

FY2021 FY2022 FY2023 FY2024 FY2025 FY2021 FY2022 FY2023 FY2024 FY2025
15.1% 22.2% 24.5% 26.1% 25.4%

Profit before tax1 (INR million and margin%) Profit after tax1 (INR million and margin %)

FY2021-25 CAGR2: 111% FY2021-25 CAGR2: 102%

+3.2% +0.7%
FY2020-25 CAGR: 59% FY2020-25 CAGR2: 68%
6,271 6,473 4,781 4,813

4,493 3,261
2,805 1,962

325 288
FY2021 FY2022 FY2023 FY2024 FY2025 FY2021 FY2022 FY2023 FY2024 FY2025
2.2% 12.7% 16.3% 18.7% 17.2% 1.9% 8.9% 11.8% 14.3% 12.8%

1. In FY2025, PBT and PAT is impacted due to non-recurring exceptional expense item of INR 499 million arising due to merger of MHPL with [Link] and PAT Growth in FY25 adjusted for one time expense was 11.2% y-o-y
and 8.5% y-o-y respectively 15
2. FY2021 was impacted due to Covid-19 therefore resulting in higher CAGR growth
Key operating metrics: Volumes, occupancies, ALOS
Strong volume growth, increased bed capacity and improvements in ALOS
Census and occupied beds ALOS (days)

+10.1%
3.89 -1.9%
3.76
2,440 3.25 3.23
2,049 2,231 +9.4% 3.17
1,779
1,579 1,514
1,205 1,375
1,076
814

FY2021 FY2022 FY2023 FY2024 FY2025 FY2021 FY2022 FY2023 FY2024 FY2025
52% 60% 59% 62% 62%

Census beds Occupied beds

IPD volumes (‘000) OPD volumes (‘000)

+11.7% +9.5%
174 2,937
156 2,683
135 2,275
1,971
102
76
1,102

FY2021 FY2022 FY2023 FY2024 FY2025 FY2021 FY2022 FY2023 FY2024 FY2025

16
 Key operating metrics: ARPOB and revenue mix
IPD Revenue mix by payor is changing due to uptick in scheme business at Patna and Lucknow
ARPOB* (INR) IPD Revenue mix by payor category**
+1.3%

59,098 61,890 62,722

54,547
47,731 62% 60% 63% 61% 57%

23% 25% 24% 3% 24% 25%

4% 4% 4% 4%
9% 2% 9% 2% 9% 2% 9% 2% 10 4%
FY2021 FY2022 FY2023 FY2024 FY2025 FY2021 FY2022 FY2023 FY2024 FY2025
Cash TPA CGHS/ ECHS/ Indian Railways PSU & Corporate Others

Domestic and international revenue breakdown IPD vs OPD revenue breakdown

4% 4% 6% 6% 6% 16% 17% 17% 16% 16%

96% 96% 94% 94% 94%

84% 83% 83% 84% 84%

FY2021 FY2022 FY2023 FY2024 FY2025

FY2021 FY2022 FY2023 FY2024 FY2025

International Domestic OPD IPD

1. ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days
17
2. IPD revenue mix by payor category is based on payment type
 Diverse revenue1 mix across all complex specialties
Significant contribution from complex specialties, cancer contribution is increasing

Heart 20.6% 20.9% 23.8% 23.1% 21.6%

Digestive 11.7% 10.2% 11.3%

12.0% 11.4%

10.8%
Cancer 12.3% 13.7%
11.5% 12.3%
11.2%
Neuro 10.5%
11.4% 11.2% 11.4%
7.2%
Kidney & Urology 8.0%
7.5% 7.6% 7.6%
11.3%
Internal Medicine 10.9% 6.9% 6.2% 6.6%
Ortho 4.5% 4.7% 4.8%
3.7% 5.1%
4.0% 3.6% 3.4% 3.1%
Liver Transplant 3.9%

Others 18.4% 20.4% 17.9% 20.2% 19.9%

FY2021 FY2022 FY2023 FY2024 FY2025

Notes:
1. Revenue from healthcare services excludes pharmacy revenue and other income
2. Revenue breakdowns are provided as per internal MIS at the Company’s consolidated level
3. Cancer includes medical oncology, radiation oncology, head & neck surgery, bone marrow transplant and breast surgery

18
 Volume led growth in both mature and developing hospitals
Patna delivered robust growth during the year, offset by subdued performance in Lucknow during H1 FY25
Matured hospitals - Over 6 years Developing hospitals - Less than 6 years
Total Income (INR million) EBITDA (INR million and margin %) Total Income (INR million) EBITDA (INR million and margin %)

+10.6% +12.1% +10.0% +1.8%

26,119 6,481 10,940 3,233 3,290
23,606 5,779 9,948

FY2024 FY2025 FY2024 FY2025 FY2024 FY2025 FY2024 FY2025

24.5% 24.8% 32.5% 30.1%

Occupied Bed Days ARPOB* (INR) Occupied Bed Days ARPOB* (INR)
+5.4% +4.6% +18.7% -4.3%

337,280 355,526 64,748 67,755 196,966 56,726 54,303

165,959

FY2024 FY2025 FY2024 FY2025 FY2024 FY2025 FY2024 FY2025

62% 64% 61% 59%

*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days
 Matured and Developing hospitals number have been restated due to the merger of MHPL (Lucknow Unit) with GHL (holding company). The intercompany transactions between two companies were eliminated as per
the requirement of accounting standards 19
 Previous period figures have been regrouped/reclassified to conform to the current period's classification
03 Q4 FY2025 Performance Update

20
 Q4 FY2025 performance summary
Delivered strong Revenue and EBITDA y-o-y growth of 14% and 20% respectively, led by volume growth

Adjusted PAT*
INR 9,542 million INR 2,476 million INR 1,014 million INR 1,387 million
Total Income

Margin: 26.0% Margin: 10.6% Margin: 14.5%

EBITDA

PAT
Q4 FY24 Q4 FY24 Q4 FY24 Q4 FY24
8,361 million 14.1% 2,068 million
Margin: 24.7% 19.8% 1,273 million
Margin: 15.2% -20.4% 1,273 million
Margin: 15.2% 8.9%

Patient Footfalls
42,901 718,008
Occupied Bed

136,761 63,629 3.19

ARPOB* (INR)

ALOS (days)
In-patients Out-patients
Days

Q4 FY24 Q4 FY24 Q4 FY24

121,834 12.3% 63,063 0.9% 3.27 -2.6% 15.2% 12.9%
Q4 FY24 Q4 FY24
37,238 635,952

* In Q4 FY25 and FY25, PBT and PAT is impacted due to non-recurring exceptional expense item of INR 499 million arising due to merger of MHPL with GHL

1. ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days
21
2. Outpatients volume reflects OPD encounters
Q4 FY2025 performance summary
Quarter performance led by strong growth in developing units

• Consolidated Total Income of INR 9,542 million, grew by 14.1% y-o-y, primarily led by patient volume growth

• EBITDA was INR 2,476 million, growth of 19.8% y-o-y. EBITDA margins improved from 24.7% in Q4 FY24 to 26.0% in Q4 FY25

• Profit After Tax was INR 1,014 million with PAT margins of 10.6%

• In Q4 FY25 Profit After Tax is impacted due to non-recurring exceptional expense item of INR 499 million arising due to merger of
MHPL with GHL. Adjusted PAT was INR 1,387 million with margins of 14.5% and growth of 8.9% y-o-y

• Occupied bed days increased by 12.3% y-o-y, representing an occupancy of 61.3% on increased bed capacity

• ARPOB grew marginally by 0.9% y-o-y to 63,629 in Q4 FY25. In-patients count increased by 15.2% and Out-patients count increased by
12.9% y-o-y

• Matured hospitals revenue was INR 6,541 million, growth of 8.0% on y-o-y basis. EBITDA was INR 1,685 million, growth of 12.9% y-o-y
• Developing hospitals revenue was INR 2,814 million, growth of 24.2% on y-o-y basis. EBITDA was INR 850 million, growth of 35.6% y-o-y

• During the quarter, International Patients Revenue increased by 17% y-o-y to INR 557 million, driven by increased international patient
volume
• OPD Pharmacy (Hospital & Retail) business continues to register strong growth. Revenue increased by 27.3% y-o-y to INR 340 million in
Q4 FY25

Notes:
 Matured and Developing hospitals number have been restated due to the merger of MHPL (Lucknow Unit) with GHL (holding company). The intercompany
transactions between two companies were eliminated as per the requirement of accounting standards
 Previous period figures have been regrouped/reclassified to conform to the current period's classification

22
• ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days
Key operating metrics: Revenue and profitability
Registered strong Total Income and EBITDA y-o-y growth of 14% and 20% respectively in Q4 FY25
Total Income (INR million) EBITDA (INR million and margin %)

+14.1%
+19.8%
9,595 9,542
8,361 2,538 2,476
2,068

Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25

24.7% 26.5% 26.0%

Profit before tax (INR million and margin%) Profit after tax (INR million and margin %)

-6.8% -20.4%
1,891 1,429
1,273
1,431 1,334 1,014

Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25

17.1% 19.7% 14.0% 15.2% 14.9% 10.6%

• In Q4 FY25, PBT and PAT is impacted due to non-recurring exceptional expense item of INR 499 million arising due to merger of MHPL with 23
GHL. PBT and PAT Growth in Q4 FY25 adjusted for one time expense was 28.1% y-o-y and 8.9% y-o-y respectively
Key operating metrics: Volumes, occupancies, ALOS
Strong volume growth, increased bed capacity and improvements in ALOS
Census and occupied beds ALOS (days)

+13.2% -2.4%
2,480 2,480 3.27 3.23 3.19
2,256 +9.9%
1,577 1,518
1,341

Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25

59% 64% 61%

Census beds Occupied beds

IPD volumes (‘000) OPD volumes (‘000)

+15.2% +12.9%
45 43 720 718
37 636

Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25

24
 Key operating metrics: ARPOB and revenue mix
ARPOB marginally grow due to change in speciality mix
ARPOB* (INR) IPD Revenue mix by payor category
+0.9%
63,063 61,307 63,629
59% 55% 57%

24% 27% 25%

4% 5%
9% 3% 10% 3% 10% 4%
4%
Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25
Cash TPA CGHS/ ECHS/ Indian Railways PSU & Corporate Others

Domestic and international revenue breakdown IPD vs OPD revenue breakdown

6% 6% 6% 16% 15% 16%

94% 94% 94% 84% 85% 84%

Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25

International Domestic OPD IPD

25
*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days
 Growth seen in both mature and new hospitals
Developing hospitals continues to deliver strong revenue and EBITDA growth
Matured hospitals - Over 6 years Developing hospitals - Less than 6 years
Total Income (INR million) EBITDA (INR million and margin %) Total Income (INR million) EBITDA (INR million and margin %)

+8.0% +12.9% +24.2% +35.6%

6,057 6,541 1,685 2,814 850

1,493 2,265 627

Q4 FY24 Q4 FY25 Q4 FY24 Q4 FY25 Q4 FY24 Q4 FY25 Q4 FY24 Q4 FY25

24.7% 25.8% 27.7% 30.2%

Occupied Bed Days ARPOB* (INR) Occupied Bed Days ARPOB* (INR)
+1.6% +5.8% +36.3% -6.7%
84,303 85,624 65,746 69,592 51,137 57,696 53,818
37,531

Q4 FY24 Q4 FY25 Q4 FY24 Q4 FY25 Q4 FY24 Q4 FY25 Q4 FY24 Q4 FY25

63% 62% 58% 60%

*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days
 Matured and Developing hospitals numbers have been restated due to the merger of MHPL (Lucknow Unit) with GHL (holding company). The intercompany transactions between two companies were eliminated as per
the requirement of accounting standards 26
 Previous period figures have been regrouped/reclassified to conform to the current period's classification
04 Project Update and Capex Plan

27
Noida hospital construction update
97% superstructure complete; MEP work in progress. Expected to commence operations in Q2 FY26

• Project situated in sector 50 Noida,

close proximity to metro station
• Greenfield project, with bed capacity of
550 beds
• Construction started in September
2022
• Mechanical Electrical, Plumbing and
interior finishing work in progress
• Hospital expected to commence
operations with 300 beds in Q2 FY26
• Designed for delivering highest level of
patient care, the project has received
pre-certification of Green Building
Certification under IGBC Green
Healthcare Facilities Rating System by
CII-Indian Green Building Council

*Actual images

28
Medanta to enter Mumbai market with a state-of-the-art, 500+ bedded
super-specialty hospital at Oshiwara, Mumbai

Super specialty hospital in Oshiwara, Mumbai

 The Company has bought 8,859 sq. meters of land in Oshiwara from MHADA for an
amount of INR 125.11 crores in a public auction

 In addition, the company need to purchase additional FSI from MHADA

 The facility is expected to have a capacity of 500+ beds and will set new
benchmarks in healthcare delivery, providing world-class medical services and
advanced treatment options to the residents of Mumbai and surrounding regions

 The project cost including Land and FSI purchase is estimated to be in the range
of ~INR 1,200 crores

 Final plot area is now 9,287.54 sqm after final measurement and company has
paid INR 6.05 crores for additional area of 428.34 sqm

 Barricading of the site has been completed. IOA approval has been obtained,
application for commencement of construction upto plinth level filed

 Soil testing is complete, and the structural consultant is currently designing

the shoring, excavation, and basement construction plan based on the test
*The artistic image for illustration purpose only results. The process for FSI purchase is currently underway

INR 125.11 crores

Lease Agreement Barricading and
Tender Won
Signed Security Complete
Bid Amount Paid

29
Delhi: Strengthening our presence in the region with a planned capacity of ~1,150 beds
Expanding into the high-growth, densely populated micro markets of Northwest and South Delhi

Super specialty hospital in North West Delhi Super specialty hospital in South Delhi

*The artistic image for illustration purpose only

*The artistic image for illustration purposes only
• Medanta has signed an Operations and Management Agreement with
Society to operate and manage a ~750 bed super speciality hospital at • ~400-bed super specialty hospital in South Delhi
Pitampura, New Delhi • DLF and Medanta will contribute equity in equal proportion (50:50)
• 7-acre site in Pitampura, with a total built-up area of 7.6 Lakh [Link] • Medanta will run the hospital and have operational control; DLF will be a
excluding the basement strategic investor
• The hospital is to be jointly built by Medanta and Society over next ~4 years, • SPV named “GHL Hospital Limited” was formed in December 2023
subject to necessary statutory and customary approvals
• Barricading is currently in progress at both sites. Soil testing has been
• Medanta is expected to incur a project capex of ~INR 600 crores, to be completed on site 1
funded by a combination of internal accruals and debt financing
• The tender process for excavation and D-wall works has been initiated.
• Architectural drawings are currently under preparation. Construction
Formal appointments of all consultants are underway
will commence upon receipt of the building permit, based on the
drawings

30
 Completing the campus
Establishing world class medical college and guest house for out of city patients

Medanta Medical College Medanta Guest House

*The artistic image for illustration purposes only *The artistic image for illustration purposes only

• Medanta to construct a service apartments / guest house on the

• Establish a world-class, future-ready Medical College in
“Medanta-The Medicity” Gurugram campus
Gurugram which would provide high quality education of
global standards • This project with an investment of ~INR 250 crores will cater to the
growing demand from international as well as out of town domestic
• Documentation process of obtaining necessary regulatory
patients
approvals from the State and National Medical Council (NMC)
has been initiated • This facility will also help us optimize length of stay in our Gurugram
hospital by providing continuity of care in a safe and secure out of
• Architectural drawings are currently under preparation
hospital environment
• Architectural drawings currently under preparation. D-wall order
released

31
 On-going expansion projects
Planned bed capacity addition; well positioned to drive near term growth

Number of installed beds ~2,000 bed addition

+50.3%

400
~1,000 bed addition
750
~219 bed addition +33.9% 400 500
+7.8%
100 50 250
100 100
2,823 110 22 300 6,124
49 58 112
3,042 4,074

31-Mar-24Gurugram Lucknow Patna FY25e Ranchi Patna - Noida - Lucknow Patna - Lucknow Patna Noida FY27e South Mumbai Pitampura,Guwahati
New - Q1 FY26 Q2 FY26 - H2 FY26 Q4 FY26 Delhi Delhi
Q1 FY26

 Gurugram:, Inaugurated dedicated floor for mother and child with 49 beds (including 25+ dedicated neonatal beds) in Q1 FY25

 Lucknow: Total 98 beds added in March 2024 and 58 beds added in FY2025

 Patna: Total 112 beds including 55 census beds and 57 day care beds comprising of 39 Dialysis and 17 Chemo beds added in FY2025

 Ranchi: Lease agreement signed to operate and manage a newly built 110 bedded hospital in Ranchi, expected to operationalize in Q1 FY26

 Noida with total capacity of 550 beds: 300 beds planned expected to operationalise by Q2 FY26

 South Delhi: Announced 400 bed in partnership with DLF. Site survey complete, soil testing complete and barricading is in progress

 Mumbai: Land acquired in Mumbai in October 2024. Barricading of the land is complete. Architectural drawings are currently under preparation

 Pitampura, New Delhi: Signed O&M Agreement to jointly build and operate and manage a ~750 bed hospital. Architectural drawings are currently under
preparation

 Guwahati, Assam: Board has approved the project to build a 400 bedded hospital in Guwahati. Land purchase is in progress (announced in April, 2025)
Indore*: : A 300-bed facility was announced in partnership with a real estate partner. However, the project is currently under review by the company due to ongoing legal 32
proceedings involving the erstwhile owner. Given the uncertainty around timelines, the project has been excluded from the current bed build-out plan.
Capex plan next 5 years
Total capex of over ~INR 3,500 crores planned for next 5 years for ~3,000 bed addition

250
300
510

587

4,051
1,063 3,501

300
459
450 109
23

Maintenance Ranchi Lucknow Noida South Mumbai Pitampura, Guwahati Medical Guest Total
Capex for 3 New and Patna Delhi- DLF Delhi School House Capex
Years

 In FY2025, INR 645 crores of capex incurred including INR 137 crores related to Mumbai project

 Maintenance capex and capex on bed addition at Lucknow, Patna and Ranchi new unit estimated at ~600 crores to be
incurred over next three years

 Total Project capex estimated at INR ~4,000 crores, to be funded by combination of Debt funding and internal accruals

33
 Medanta’s Journey, Purpose and
05
Model of Healthcare

34
Medanta was founded to bring a new type of healthcare to India…
… the human side of healthcare

Healthcare is never only about science. It is also about the art of

medicine – the human connection, putting the patient first,
collaboration, the personal acts of empathy and the values that
guide our decision making.

“ At Medanta we have built an institution to match the

highest benchmarks of excellence globally. We have
created an ecosystem of excellence that encompasses
world-leading clinicians, state-of-the-art equipment,
best-in-class infrastructure, and a strong emphasis on
research and innovation.
Medanta’s patient-first approach allows teams of
super-specialist doctors to collaborate seamlessly and
arrive at the best-possible treatment customized for
each patient in line with our guiding philosophy ‘Har
“ Dr. Naresh Trehan
Ek Jaan Anmol’, meaning ‘Every Life is Invaluable’ CMD & Chief Cardiac Surgeon, Medanta

35
 Growth from a single flagship hospital in Gurgaon…
…to a network of 5 high quality hospitals across north India

2026E
MEDANTA
2025 HOSPITAL
MEDANTA NOIDA
2021 HOSPITAL
Plan for 550 beds
JAI PRABHA Ranchi** Expected to
2019 MEDANTA SPECIALTY begin phase I
110 Beds
MEDANTA HOSPITAL operations with
Expected to
2015 HOSPITAL
PATNA commence ~300 beds in
MEDANTA ABDUR LUCKNOW operations Q2FY26
RAZZAQUE ANSARI 650 Beds
2014 950 Beds 470 currently by end of Q1 FY26
MEMORIAL WEAVERS
MEDANTA HOSPITAL 757 currently operational including
SUPER SPECIALTY operational 140 ICU beds
2009 HOSPITAL RANCHI including 202 ICU
MEDANTA 200 Beds beds
INDORE
THE MEDICITY 54 ICU Beds
175 Beds
Gurgaon 53 ICU Beds
1,440 Beds
316 ICU Beds IPO
2015
Temasek buys
minority stake in
January
2022
Global Health Ltd
2013 IPO listed on BSE
Carlyle* buys
and NSE on 16th
minority stake in
November*
December

• *Carlyle Group (Anant Investments) exited completely in the IPO

36
• ** Medanta to operationalize ~110 bedded newly built hospital in Ranchi under an O&M arrangement
From our flagship Medicity campus in Gurgaon, we have grown to ~3,042
beds across 5 cities
Largest private hospital beds in operation under one roof in Delhi (NCR), Uttar Pradesh and Bihar

Gurgaon LUCKNOW PATNA

1,440 beds; 316 ICU beds 757 beds; 202 ICU beds (950 planned) 470 beds; 140 ICU beds (650 planned)

INDORE RANCHI* NOIDA

175 beds; 53 ICU beds 200 beds; 54 ICU beds 550 total beds (under construction)

All beds are installed beds as at March 31, 2025 37

* Medanta has signed an O&M agreement to manage for a ~110 bedded newly built hospital in Ranchi
 Our Mission and Values
Embracing a new era and redefining our purpose

Core Values

Patient centric care: Foster a culture where every one of us is

MISSION committed to care for patients and their caregivers

Our mission is to deliver Leadership and quality: Commit to delivering excellence in

world class, patient everything we do through exemplary action and behaviour
centric, integrated and
affordable healthcare
Integrity and courage: Maintain the highest ethical
through a dynamic
standards by putting the patient first and demonstrating the
institution that focuses courage to do what is right
on the development of
people and knowledge
Collaboration, learning and innovation: Promote teamwork
and collaboration, welcome change and creativity,
encourage innovation

38
The Medanta Model of Healthcare
Delivering the highest quality of medicine with care and compassion

Exceptional clinical
talent
What it means for patients and
caregivers?

• Super specialized doctors provide the

highest quality of care through a team
based integrated approach
Trust based
compassionate World class • A safe and friendly healing environment
care Infrastructure with a patient-centric design in all
clinical areas and public spaces
Model of
• Availability of the most advanced,
Healthcare
innovative equipment and technology to
enable the most complex diagnostics
and treatment

• Doctors who take ownership and

personal responsibility
Caring systems and Latest high end
• Respect-based processes for patients
processes technology
and their families

39
Exceptional clinical talent delivering the highest end of care
World leading clinicians deliver multispecialty integrated care through a doctor led model

1 Clinical team includes recipients of Padma Bhushan, 5 Almost all doctors work full-time and exclusively at
Padma Shri, and BC Roy awards, in addition to other Medanta’s hospitals
accolades

2 Senior doctors trained in leading medical institutions 6 Each specialty operates on a joint rewards system to
mentored in the Medanta way promote a team based approach to care delivery

3 Departmental concept enables sub-specialisation, and 7 Culture of collaboration, cooperation and teamwork with
ensures a combined team-based approach to care multispecialty care integration

4 Autonomy given to each department head to focus on 8 30+ medical specialties led by specialist teams of
the medicine and to drive clinical excellence doctors with an aim to deliver the best medicine

40
 Infrastructure designed to create a safe and efficient environment
World class infrastructure that creates the best possible space for healing

• High proportion of OTs and ICUs; given the orientation

towards higher end, complex clinical work
• High focus on infection control practices; dedicated Air
Handling Units (AHUs) for each OT, ICU and ward
• Strong focus on patient safety (including fire safety)
with JCI compliant infrastructure
• Co-horting of patient’s with the same disease profile on
SPACES DESIGNED TO PATIENT CENTRIC
one floor to give a ‘hospital within a hospital’ feel for
OPTIMIZE CLINICAL DESIGN FOCUSED ON
each specialty
FLOWS QUALITY AND SAFETY
• Spaces designed to optimize ease of clinical flows with
high square foot to bed ratios and wide corridors
• Natural light in every patient space including ICUs; to
help align patients time cycles to natural cycles of the
sun
• Modular design across all units; to enable easy
movement as per occupancy and specialty needs

41
High standard of care enabled by the latest sophisticated technology
Providing the latest tools to enable our doctors to deliver the greatest care
Artis-Zeego Da Vinci Robotic
Endovascular Biplane Cath Lab
System
Surgical Cath Lab
Enables cardiologists and Enables surgeons to Used for highly
surgeons to work together perform delicate and advanced cranial
on complex procedures complex minimally procedures
such as aortic dissections invasive surgeries

Cyberknife VSI
Robotic Radiosurgery ZEISS KINEVO 900 S Brain SUITE
System Next-generation robotic
visualization system
Non-invasive alternative State of the art
with 3D imaging,
to surgery for the treatment neurosurgery operating
advanced optics, and
of both cancerous and non- theater which includes
precise for complex
cancerous tumours an MRI inside the OT
microsurgeries

MAGNETOM Vida Da Vinci Xi Single

1,152-Slice CT
3-Tesla MRI robotic system
Advanced AI based CT single console
First 3T MRI scanner with
scanner for highly
BioMatrix technology Offers unparalleled precision
accurate CT procedures
provides improved and control for minimally
and better evaluation of
perfusion imaging, invasive, high-precision
complex heart related
myocardial tagging and surgeries across multiple
diseases
MR angiography specialties

42
Experienced senior management team across units
Clinical department heads chair operating and governance committees in each unit

Dr Naresh Trehan Pankaj Sahni Yogesh Kumar Gupta

Chairman and Group CEO & Chief Financial Officer
Managing Director Director

Bhuvander Kaul Dr Sandeep Sawhney Rajiv Sikka

Chief Procurement Chief Strategy Officer Chief Information
Officer Officer

s
Saurabh Upadhyay Richa Singh Rahul Ranjan
SVP and Head HR General Counsel Company Secretary

Dr Pankaj Dr Rakesh Dr Ravi Dr Dr Sanjay Vishvajeet

Dhamija Kapoor Shankar Geed Kumar
Hospital Medical Medical Medical Hospital
Director, Director, Director, Director, Director,
Gurugram Lucknow Patna Indore Ranchi

43
Eminent Board of Directors
Marquee domestic and foreign institutions as major shareholders

Others
Board of Directors 10.25%
Promoter
FII
33.03%
11.76%
Shareholding
Mutual Funds
pattern as on 10.36%

Dr Naresh Trehan Pankaj Sahni Sunil Sachdeva 31st March, 2025

Chairman and Group CEO & Director Non-Executive Sunil Sachdeva
Managing Director Director 11.27%

RJ Corp Limited Dunearn Investments*

6.59% 16.72%

Ravi Kant Jaipuria Ms. Praveen Mahajan Vikram Singh Mehta

Non-Executive Independent Director Independent Director
Nominee Director Top
institutional
investors as on
31st March, 2025
Hari Shanker Bhartia Rajan Bharti Mittal Ravi Gupta
Independent Director Independent Director Independent Director

Note: All logos used for representation purpose only and copyrights belongs to their respective owners

* Temasek affiliates 44
Medanta is well placed to deliver sustainable growth…
…while maintaining its core values of patient centric care and clinical leadership and quality

CONTINUITY OF
CARE
TECHNOLOGY
Extend clinical THOUGHT
ADVANCEMENT
services outside LEADERSHIP
Use technology to hospital and
ENHANCE Build on our
improve patient across patient
CAPABILITIES thought leadership
experience and grow lifetime
Add new digital health through academics
specialties and and research
ATTRACT BEST improve operating
TALENT efficiencies
Engage prominent,
skilled clinical talent
BED EXPANSION
In existing and
new hospitals

45
 Aligning strategy with values to deliver positive results for all stakeholders
Growth you can be proud of

• Deliver the highest end of patient centric care by embracing the sickest
patients and treating the most complex cases

• Maintain our leadership and quality by strengthening our already

exceptional clinical talent by adding new doctors and new services

• Drive innovation, collaboration and learning through digital and

technology improvements which improve ease of access and efficiency of
care to our patients

• Maintain the courage and integrity to always do what is right and work in
the best interests of our patients, our employees, our investors and our
community. We continue our bed build out and deliver our ‘Medanta
Model of Care’ to those communities where healthcare services remain
underpenetrated

46
06 Annexures

47
 Annexure: Profit and Loss Statement
Year End Quarter

INR million FY24 FY25 Y-o-Y Growth % Q4 FY24 Q3 FY25 Q4 FY25 Y-o-Y Growth %

Revenue from operations 32,751 36,923 12.7% 8,086 9,434 9,312 15.2%

Other income 747 791 5.9% 274 160 229 (16.4)%

Total income 33,498 37,714 12.6% 8,361 9,595 9,542 14.1%

Cost of materials consumed 7,594 8,797 15.8% 1,937 2,292 2,136 10.3%

Employee benefits expense 11,619 13,219 13.8% 2,959 3,300 3,356 13.4%

Other expenses 5,548 6,137 10.6% 1,397 1,465 1,573 12.6%

EBITDA 8,737 9,562 9.4% 2,068 2,538 2,476 19.8%

EBITDA Margins % 26.1% 25.4% (73) bps 24.7% 26.5% 26.0% 122 bps

Finance costs 739 653 (11.7)% 182 163 150 (17.5)%

Depreciation and amortisation

1,727 1,937 12.2% 455 484 493 8.4%
expense

Exceptional item 0 499 na 0 0 499 na

Profit before tax 6,271 6,473 3.2% 1,431 1,891 1,334 (6.7)%

Tax expenses 1,490 1,659 11.3% 157 462 321 103.7%

Profit after tax 4,781 4,813 0.7% 1,273 1,429 1,014 (20.4)%

• In Q4 FY25 and FY25, PBT and PAT is impacted due to non-recurring exceptional expense item of INR 499 million arising due to merger of MHPL with GHL. PAT Growth in Q4 FY25 and FY2025 adjusted for one time expense
48
was 8.9% y-o-y and 8.5% y-o-y
 Annexure: Operational Parameters
Year End Quarter

Key metrics FY24 FY25 Y-o-Y Growth % Q4 FY24 Q3 FY25 Q4 FY25 Y-o-Y Growth %

Total Beds 2,823 3,042 7.8% 2,823 3,042 3,042 7.8%

Census Beds 2,231 2,440 9.4% 2,256 2,480 2,480 9.9%

Occupied Bed Days 503,239 552,492 9.8% 121,834 145,095 136,761 12.3%

Occupancy Rate % 61.6% 62.0% 38 bps 59.4% 63.6% 61.2% 178 bps

ARPOB (INR)* 61,890 62,722 1.3% 63,063 61,305 63,629 0.9%

ALOS (days) 3.23 3.17 (1.7)% 3.27 3.23 3.19 (2.6)%

In-Patient Volumes 1,55,915 1,74,219 11.7% 37,238 44,856 42,901 15.2%

Out-Patient Volumes 2,683,293 2,937,400 9.5% 635,952 720,305 718,008 12.9%

• Census Beds as based on monthly average during the period

• ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days
• Out-Patient volumes are sum of encounters at Out-Patient departments

49
Annexure: Abbreviations and Definitions
Abbreviations
 INR : Indian Rupee
 NABH : National Accreditation Board for Hospitals & Healthcare Providers
 NABL : National Accreditation Board for Testing and Calibration Laboratories
 JCI : Joint Commission International
 OPD : Out-Patient Department
 IPD : In Patient Department
 ICU : Intensive Care Unit
 Mn : Million
 ARPOB : Average Revenue Per Occupied Bed
 ALOS : Average Length of Stay
 EBITDA: EBITDA represents Profit before tax after adding back finance costs and depreciation and amortization of the relevant year/period
 EBITDA Margin : EBITDA divided by Total Income in percentage
 PAT : Profit After Tax
 NCR : National Capital Region

Definitions
 Bed Capacity / Installed Beds : Total Bed available in the hospital (including census (bed available for mid-night occupancy) and non-census beds (all other
bed available other than census beds, i.e., day-care beds).
 Occupied beds : Total Count of patients at midnight at each day
 Average Occupancy Levels : (Total Occupied beds/Total census beds) i.e. Excluding day Care bed, Emergency, Dialysis beds, Pre & post catherization &
Observation room
 ICU Beds: No of ICU Beds available in the hospital out of census beds
 Total Income : Revenue from Operations + Other Income
 ARPOB : Income from Health Care Services excluding Pharmacy and Other Income revenue divided by occupied bed days
 ALOS : Average number of days spent by admitted inpatients
 Revenue mix by Payment Type, i.e. Cash, TPA,CGHS, ECHS, PSU others.

50
Contact us
About Medanta Contact Details

Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and Ravi Gothwal –

cardiothoracic surgeon who has been awarded the prestigious
Padma Bhushan and the Padma Shri, the third- and fourth-highest
Head of Investor Relations
civilian awards in India, and the Dr. B.C. Roy Award in recognition of
his distinguished contribution to medicine. +91 95996 55711

Global Health Limited (the “Company”) is one of the largest private

multi-specialty tertiary care providers operating in the North and
[Link]@[Link]
East regions of India, with key specialties cardiac science,
neurosciences, oncology, digestive and hepatobiliary sciences,
orthopedics, liver transplant, and kidney and urology, according to
Corporate Office
the report titled “An assessment of the healthcare delivery market in
India, September 2022” by CRISIL Limited. Medanta; The Medicity
CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector 38,
Under the “Medanta” brand, the Company has a network of five
Gurgaon, Haryana 122001
hospitals currently in operation (Gurgaon, Indore, Ranchi, Lucknow,
and Patna). Spanning an area of 4.7 million sq. ft., its operational
hospitals have 3,042 installed beds as on March 31, 2025. It also has For further information, please visit our website:
one hospital under-construction in Noida. The Company provides
healthcare services in over 30 medical specialties and engages over [Link]
1,800+ doctors led by highly experienced department heads.

51